Germany-headquartered Siemens Healthineers has uncoupled China from the rest of its Asia business to maximize opportunities in the world’s largest medtech market-in-waiting.

While revenues are looking healthier at last, a host of issues in the post-COVID readjustment phase still weigh heavily on medtech manufacturers in Germany, chief among which is EU and national over-regulation. Hospital reform and the digital shift are also on a long list of priority issues to monitor and tackle if Germany’s industrial base is to remain preeminent, said BVMed chief executive Marc-Pierre Möll.

Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.